Maternal vaccination against RSV can substantially reduce childhood mortality in low-income and middle-income countries: A mathematical modeling study

Maternal vaccination against RSV can substantially reduce childhood mortality in low-income and middle-income countries: A mathematical modeling study

Blog Article

Background: Respiratory syncytial virus (RSV) is a leading cause of childhood mortality in infants below 6 months of age.In low-income and middle-income countries (LMICs), the public health burden is substantial and resources are limited.It is critical to inform decision makers about effectiveness of new interventions.

Methods: We developed a mathematical model where individual RSV subtype A (RSV-A) and B (RSV-B) maternally derived neutralizing titers were predicted at time of birth after maternal vaccination with the RSV prefusion F protein-based vaccine.We estimated the subsequent duration of vaccine-induced immunity ALL IN ONE NUTRITIONAL SHAKE VANILLA and compared this to the age at time of death distribution in the RSV GOLD Mortality Database to predict the potential impact of maternal vaccination on RSV-related childhood mortality.We used country-specific timing of antenatal care visits distributions and mortality estimates to make country-specific predictions for number of cases averted.

Findings: The model predicts that on average a neonate born at 40 weeks gestational age will be protected between 6 and 7 months from RSV-A and approximately 5 months from RSV-B related mortality.We estimated the potential impact of RSV-related mortality for in-hospital and out-of-hospital cases in LMICs and predicted that in 51 GAVI-eligible countries maternal vaccination could avert between 55% and 63% of the RSV-related in-hospital mortality cases below 6 months of age.Interpretation: We show that maternal vaccination could substantially decrease RSV-A and RSV-B related in-hospital and out-of-hospital mortality in LMICs in the first 6 months MENS SINGLETS of life.